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Proteoglycans (PGs) are a major component of the extracellular matrix in many tissues and function as structural and regulatory
molecules. PGs are composed of core proteins and glycosaminoglycan (GAG) side chains. The biosynthesis of GAGs starts with the linker
region that consists of four sugar residues and is followed by repeating disaccharide units. By exome sequencing, we found that B3GALT6
encoding an enzyme involved in the biosynthesis of the GAG linker region is responsible for a severe skeletal dysplasia, spondyloepi-
metaphyseal dysplasia with joint laxity type 1 (SEMD-JL1). B3GALT6 loss-of-function mutations were found in individuals with
SEMD-JL1 from seven families. In a subsequent candidate gene study based on the phenotypic similarity, we found that B3GALT6 is
also responsible for a connective tissue disease, Ehlers-Danlos syndrome (progeroid form). Recessive loss-of-function mutations in
B3GALT6 result in a spectrum of disorders affecting a broad range of skeletal and connective tissues characterized by lax skin, muscle
hypotonia, joint dislocation, and spinal deformity. The pleiotropic phenotypes of the disorders indicate that B3GALT6 plays a critical
role in a wide range of biological processes in various tissues, including skin, bone, cartilage, tendon, and ligament.Skeletal dysplasias represent a vast collection of genetic dis-
orders of the skeleton, currently divided into 40 groups.1
Spondyloepimetaphyseal dysplasia (SEMD) is one group
(group 13) of skeletal dysplasia that contains more than
a dozen distinctive diseases. SEMD with joint laxity
(SEMD-JL) is a subgroup of SEMD that consists of type 1
(SEMD-JL1 [MIM 271640]) and type 2 (SEMD-JL2 [MIM
603546]). SEMD-JL1 or SEMD-JL Beighton type is an auto-
somal-recessive disorder that shows mild craniofacial dys-
morphism (prominent eye, blue sclera, long upper lip,
small mandible with cleft palate) and spatulate finger
with short nail.2 The large joints of individuals with
SEMD-JL1 are variably affected with hip dislocation, elbow
contracture secondary to radial head dislocation, and club-
feet. Joint laxity is particularly prominent in the hands.
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The Amate platyspondyly with anterior projection of the vertebral
bodies, hypoplastic ilia, and mild metaphyseal flaring.3
Kyphoscoliosis progresses with age, leading to a short
trunk, whereas platyspondyly become less conspicuous
and the vertebral bodies appear squared in shape with
age. Recently, dominant kinesin family member 22
(KIF22 [MIM 603213]) mutations have been found in
SEMD-JL2;4,5 however, the genetic basis of SEMD-JL1 re-
mains unknown.
To identify the SEMD-JL1-causing mutation, we
performed whole-exome sequencing experiments. We
recruited seven individuals with SEMD-JL1 from five
unrelated Japanese families (F1–F5) and a Singapore/
Japanese family (F6) (Table 1). One family (F1) had a pair
of affected sibs (P1 and P2) from nonconsanguineous par-
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Table 1. Clinical and Radiographic Findings of the Individuals with B3GALT6 Mutations
Subject ID P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12
Family ID F1 F1 F2 F3 F4 F5 F6 F7 F8 F9 F9 F10
Clinical diagnosis SEMD-JL1 SEMD-JL1 SEMD-JL1 SEMD-JL1 SEMD-JL1 SEMD-JL1 SEMD-JL1 SEMD-JL1 EDS-PF EDS-PF EDS-PF EDS-PF
General Information
Ethnicity Japanese Japanese Japanese Japanese Japanese Japanese Japanese/
Singaporean
Vietnamese Italian Italian/
Canadian
Italian/
Canadian
Brazilian
Gender M M F M F F M M M F F F
Age 34 years 31 years 12 years,
7 months
6 years 5 years,
1 month
12 years 2 years,
9 months
34 years 8 months 7 years 1 month 5 years,
1 month
Gestational age 39 weeks,
2 days
full term 37 weeks 40 weeks,
1 day
39 weeks,
5 days
full term 39 weeks full term ND 36 weeks 37 weeks 39 weeks
Birth length (cm) ND ND 36 ND 43.1 42 43 (average) ND 44 44 44
Birth weight (g) ND 2,200 2,124 2,832 2,535 2,222 2,485 3,500 ND 2,097 2,790 3,300
Clinical Features
Height (cm) (SD)a 127.7 (7.4) 130 (7.0) 88.8 (10.7) 94 (4.0) 90 (4.0) 118.4 (5.1) 78.2 (4.0) 118 (9.1) 66 (1.6) 90 (6.8) 45 (3.7) 81 (5.9)
Weight (kg) (SD)a 40.3 (2.2) 36.9 (2.5) 13.2 (3.7) 15.4 (1.5) 14.4 (1.3) 23.2 (2.0) 10.6 (1.9) 28 (3.3) 5.65 (3.0) 13.9 (2.2) 2.65 (2.8) 8.5 (8.4)
Craniofacial
Flat face with prominent
forehead
ND ND þ þ þ þ þ – þ þ þ þ
Prominent eyes, proptosis ND ND þ – – þ þ – þ þ þ þ
Blue sclerae ND ND þ þ þ – þ – þ þ þ –
Long upper lip ND ND – þ þ – þ þ þ þ þ –
Micrognathia ND ND þ þ þ þ – þ – – – –
Cleft palate ND ND – – – – – – – – – þ
Musculoskeletal
Kyphoscoliosisb þ (7 months) þ (1.2 years) þ (8 months) þ (infancy) þ (2 years) þ (3 months) þ (8 months) þ (1 year) þ (6 months) þþ (prenatal) þþ (prenatal) þþ (2 years)
Spatulate finger – ND þ þ þ þ – – þ þ þ –
Finger laxity ND ND þ þ – – þ – þþ þ þ þ
Large joint laxity ND ND þ þ – – þ – þþ þþ þþ þ
Restricted elbow movement þ ND þ þ þ – – þ þ þ þ þ
Hand contracture – – – – – þ – – – þ þ –
(Continued on next page)
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Table 1. Continued
Subject ID P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12
Hip dislocation – – – þ – þ – – – þ þ þ
Clubfeet – – þ – – – þ – – þ þ –
Muscular hypotonia – – þ – – – – – þþ þþ þþ þþ
Skin and Hair
Doughy skin ND ND þ – – – þ – þþ þ þ þ
Hyperextensibility ND ND þ – – – þ – þþ þ þ –
Cutis laxa ND ND – – – – – – þ þ – þ
Sparse hair ND ND – – – – – – þ þ þ –
Others MR, DD camptodactyly DD pectus
excavatum
Radiological Features
Platyspondyly þc þc þc þ þ þ þ þ þ þ þ þ
Anterior beak of vertebral
bodyb
þ þ – (4 years) – (5 years) þ þ þ – þ þ þ þ
Short ilia þ þ þ þ þ þ þ þ þ þ þ þ
Prominent lesser trochanter þ þ þ – þ þ þ þ þ þ þ þ
Metaphyseal flaring þ þ þ þ þ þ þ þ þ – þ þ
Epiphyseal dysplasia of
femoral head
– – – þ – þ – – – – þ þ
Elbow malalignment ND ND þ þ þ þ þ þ þ þ þ þ
Advanced carpal ossificationb – (9 years) ND – (12 years) þ þ þ þ ND þ – (7 years) – – (5 years)
Carpal fusion ND ND þ – – – – – – – – –
Metacarpal shortening ND ND þ þ þ þ þ þ – – þ –
Overtubulation – – – – – – – – þ þ þ þ
Abbreviations are as follows: SEMD-JL1, spondyloepimetaphyseal dysplasia with joint laxity type 1; EDS-PF, Ehlers-Danlos syndrome, progeroid form; ND, o data; MR, mitral regurgitation; DD, developmental delay.
aAt last presentation.
bAge at medical attention provided in parentheses.
cAbsent at age 20 years in P1 and P2 and at age 12 years in P3.
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Figure 1. Enzymes Involved in Biosyn-
thesis of the Glycosaminoglycan Linker
Region and Summary Features of
Diseases Caused by Their Defects Based
on a Conventional Concept for the
Diseases
The biosyntheses of GAGs start with the
formation of a common tetrasaccharide
linker sequence covalently attached to
the core protein. The linker region
synthesis involves a single linear path-
way composed of four successive
steps catalyzed by distinctive enzymes.
Abbreviations are as follows: XYLT, b-xylo-
syltransferase; B4GALT7, xylosylprotein
b1,4-galactosyltransferase, polypeptide 7
(b1,4-galactosyltransferase-I); B3GALT6,
UDP-Gal, bGal b1,3-galactosyltransferase
polypeptide 6 (b1,3-galactosyltransferase-
II); B3GAT3, b-1,3-glucuronyltransferase
3 (glucuronosyltransferase I); Ser-O, the
serine residue of the GAG attachment
site on the proteoglycan core protein;
Xyl, xylose; Gal, galactose; GlcUA, D-glucuronic acid; CS, chondroitin sulfate; DS, dermatan sulfate; HS, heparan sulfate; EDS,
Ehlers-Danlos syndrome; SEMD-JL1, spondyloepimetaphyseal dysplasia with joint laxity type 1.from peripheral blood, saliva, or Epstein-Barr virus-immor-
talized lymphocyte of the individuals with SEMD-JL1 and/
or their parents after informed consent. The study was
approved by the ethical committee of RIKEN and partici-
pating institutions. We captured the exomes of the seven
subjects as previously described.6,7 In brief, we sheared
genomic DNA (3 mg) by Covaris S2 system (Covaris) and
processed with a SureSelect All Exon V4 kit (Agilent Tech-
nologies). We sequenced DNAs captured by the kit with
HiSeq 2000 (Illumina) with 101 base pair-end reads. We
performed the image analysis and base calling by HiSeq
Control Software/Real Time Analysis and CASAVA1.8.2
(Illumina) and mapped the sequences to human genome
hg19 by Novoalign. We processed the aligned reads by Pic-
ard to remove PCR duplicate. The mean depth of coverage
for reads was 132.83, and, on average, 91.0% of targeted
bases had sufficient coverage (203 coverage) and quality
for variant calling (Table S1 available online). The variants
were called by Genome Analysis Toolkit 1.5-21 (GATK)
with the best practice variant detection with the GAKT
v.3 and annotated by ANNOVAR (2012 February 23).
Based on the hypothesis that SEMD-JL1 is inherited in an
autosomal-recessive fashion, we filtered variants with the
script created byBITS (Tokyo, Japan) according to following
conditions: (1) variants registered in ESP5400, (2) variants
found in our in-house controls (n ¼ 274), (3) synonymous
changes, (4) rare variants registered in dbSNP build 135
(MAF < 0.01), and (5) variants associated with segmental
duplication. After combining variants selected by the
homozygous mutation model and the compound hetero-
zygous mutation model, we selected genes shared by indi-
viduals from three or more families. The analysis of the
next-generation sequencing identified possible compound
heterozygous variants in B3GALT6 in individuals from
three families (Table S2). In addition, two other subjects
had possible causal heterozygous variants of B3GALT6.930 The American Journal of Human Genetics 92, 927–934, June 6, 2B3GALT6 (RefSeq accession number NM_080605.3) is a
single-exon gene on chromosome 1p36.33. It encodes
UDP-Gal:bGal b1,3-galactosyltransferase polypeptide 6
(or galactosyltransferase-II: GalT-II), an enzyme involved
in the biosynthesis of the glycosaminoglycan (GAG) linker
region.8 The biosyntheses of dermatan sulfate (DS), chon-
droitin sulfate (CS), and heparin/heparan sulfate (HS)
GAGs start with the formation of a tetrasaccharide linker
sequence, glucuronic acid-b1-3-galactose-b1-3-galactose-
b1-4-xylose-b1 (GlcUA-Gal-Gal-Xyl), which is covalently
attached to the core protein. The linker region synthesis
involves a single linear pathway composed of four succes-
sive steps catalyzed by distinctive enzymes (Figure 1). The
first step is the addition of xylose to the hydroxy group of
specific serine residues on the core protein by xylosyltrans-
ferases from UDP-Xyl, followed by two distinct galactosyl-
transferases (GalT-I and II) and a glucuronosyltransferase
from UDP-Gal and UDP-GlcUA, respectively. The next
hexosamine addition is critical because it determines
which GAG (i.e., CS, DS, or HS) is assembled on the linker
region. GalT-II encoded by B3GALT6 functions in the third
step of the linker formation (Figure 1).
To confirm the results obtained by the next-generation
sequencing, we examined the seven subjects used for the
next-generation sequencing and an additional subject
from a Vietnamese family (F7) by direct sequence of the
PCR products from genomic DNAs using 3730xl DNA
Analyzer (Applied Biosystems). The Sanger sequencing
confirmed all B3GALT6 mutations found by the next-gen-
eration sequencing and identified additional B3GALT6
mutations. The results indicated that B3GALT6 mutations
were found in all subjects (Tables 2 and S1). All but P4 from
F3 were compound heterozygotes of missense mutations.
In P4, only a heterozygous c.1A>G (p.Met1?) mutation
was found, although we searched for a B3GALT6mutation
in the entire coding region, 50 and 30 UTRs, and flanking013
Table 2. B3GALT6 Mutations in Spondyloepimetaphyseal
Dysplasia with Joint Laxity Type 1 and Ehlers-Danlos Syndrome,
Progeroid Form
Family Clinical Diagnosis
Nucleotide
Change
Amino Acid
Change
F1 SEMD-JL1 c.1A>G p.Met1?
c.694C>T p.Arg232Cys
F2 SEMD-JL1 c.1A>G p.Met1?
c.466G>A p.Asp156Asn
F3a SEMD-JL1 c.1A>G p.Met1?
F4 SEMD-JL1 c.1A>G p.Met1?
c.694C>T p.Arg232Cys
F5 SEMD-JL1 c.694C>T p.Arg232Cys
c.899G>C p.Cys300Ser
F6 SEMD-JL1 c.1A>G p.Met1?
c.193A>G p.Ser65Gly
F7 SEMD-JL1 c.200C>T p.Pro67Leu
c.694C>T p.Arg232Cys
F8 EDS-PF c.353delA p.Asp118Alafs*160
c.925T>A p.Ser309Thr
F9 EDS-PF c.588delG p.Arg197Alafs*81
c.925T>A p.Ser309Thr
F10 EDS-PF c.16C>T p.Arg6Trp
c.415_423del p.Met139Ala141del
The nucleotide changes are shown with respect to B3GALT6 mRNA sequence.
The corresponding predicted amino acid changes are numbered from the
initiating methionine residue.
aOnly a heterozygous mutation was found.
Figure 2. Analyses of B3GALT6 Missense Mutant Proteins Iden-
tified in Individuals with SEMD-JL1 In Vitro
(A) Immunoblot analysis of lysates from HeLa cells expressing
transfected wild-type (WT) and mutant (c.1A>G) B3GALT6. The
mutant B3GALT6 yields a shortened protein. The difference of
the molecular sizes between WT and mutant proteins is approxi-
mately ~4 kD.
(B) Subcellular localization of B3GALT6. HeLa cells were trans-
fected withWTandmutant (c.1A>G) B3GALT6. Cells were stained
with anti-FLAG (green), anti-a-mannosidase II (red), and 40,6-dia-
midino-2-phenylindole (DAPI; blue). WT was expressed in the
Golgi, but the mutant was found in cytoplasm and nucleus.
(C) Decreased enzyme activities of the missense mutant pro-
teins (p.Ser65Gly, p.Pro67Lys, p.Asp156Asn, p.Arg232Cys, and
p.Cys300Ser). p.Glu174Asp is a common polymorphism in the
public database. The GalT-II activity is measured by incorporation
of [3H]Gal into Galb1-O-2naphthyl (pmol/ml/hr) and represents
the averages of three independent experiments performed in
triplicate. Empty and mock indicate the GalT-II activity obtained
with the conditioned medium transfected with or without an
empty vector. *p< 0.0001 versusWT (one-way analysis of variance
with Dunnett’s adjustment).regions of B3GALT6. Most of the mutations are predicted
to be disease causing by in silico analysis. The c.1A>G
(p.Met1?) mutation was found in individuals from five of
the seven families.
Although mutations affecting initiation codons have
been reported to be pathogenic in several diseases,9 the
effects of initiation codon mutations on the encoded
protein are variable among the genes. We therefore inves-
tigated the effect of the c.1A>G (p.Met1?) mutation on the
protein by using C-terminally FLAG-tagged B3GALT6 with
and without the mutation expressed in HeLa cells (RIKEN
Cell Bank). We detected the mutant B3GALT6 protein with
a molecular weight ~4 kD lower compared with the wild-
type (WT) protein (Figure 2A). These results suggest that
translation initiation at the second ATG of the coding
sequence, at position c.124, would become the initiation
codon because of the mutation, probably resulting in an
N-terminal deletion of 41 amino acids (p.Met1_Ala41del),
in the same open reading frame that contains the
transmembrane domain. We then examined the sub-
cellular localization of the mutant B3GALT6 protein by
immunocytochemistry. The immunofluorescence for WT-
B3GALT6 was observed in a perinuclear region overlappingThe Amwith that for a-mannosidase II, a marker of the Golgi as
previously reported.8 In contrast, the immunofluorescence
for the mutant B3GALT6 protein was observed in the
nucleus and cytoplasm (Figure 2B). Therefore, the mutant
protein can be considered to be functionally null because
of the mislocalization.
To investigate the causality of other B3GALT6 missense
mutations, we also examined the subcellular localization
of the mutant B3GALT6 proteins by immunocytochem-
istry. c.193A>G (p.Ser65Gly), c.200C>T (p.Pro67Leu),erican Journal of Human Genetics 92, 927–934, June 6, 2013 931
and c.694C>T (p.Arg232Cys) mutants showed mislocali-
zation, whereas c.466G>A (p.Asp156Asn) and c.899G>C
(p.Cys300Ser) mutants showed normal localization
(Figure S1). To investigate whether the B3GALT6 missense
mutations affect the enzyme function, the GalT-II activ-
ities of soluble FLAG-tagged proteins for WT and mutant
B3GALT6 proteins were assayed. The GalT-II activities of
p.Ser65Gly-, p.Pro67Leu-, p.Asp156Asn-, p.Arg232Cys-,
and p.Cys300Ser-B3GALT6 were significantly decreased
compared with WT-B3GALT6 (Figure 2C), indicating
that these mutations resulted in a loss of enzyme func-
tion. On the other hand, there were no significant differ-
ences in the GalT-II activities between WT-B3GALT6
and p.Glu174Asp-B3GALT6, a common polymorphism
(rs12085009) in the public database (Figure 2C).
All SEMD-JL1 individuals with the B3GALT6 mutation
had the characteristic skeletal abnormalities, including pla-
tyspondyly, short ilia, and elbow malalignment (Table 1
and Figure S2); however, some had a range of extraskeletal
and connective tissue abnormalities that overlapped with
those seen in Ehlers-Danlos syndrome, progeroid form
(EDS-PF [MIM 130070]). EDS-PF is an autosomal-recessive
connective tissue disorder characterized by sparse hair,
wrinkled skin, and defective wound healing with atrophic
scars.10 In addition, skeletal abnormalities so far reported
in EDS-PF are limited to generalized osteopenia and radial
head dislocation, which are in contrast with the severe
generalized dysplasias of the axial and appendicular skel-
eton observed in SEMD-JL1. Thus, both disorders at first
glance appear as separate clinical entities, although they
share the clinical features of short stature, joint laxity
and dislocation, and facial dysmorphism. In two families
with individuals with EDS-PF, recessive mutations of
B4GALT7 (MIM 604327) have been found.11,12 B4GALT7
(RefSeq NM_007255.2) encodes an enzyme, xylosylated
protein b-1,4-galactosyltransferase, that catalyzes the sec-
ond step of the GAG linker region biosynthesis (Figure 1).
Therefore, we speculated that B3GALT6 and B4GALT7
deficiencies might show similar phenotypes. We then
examined B3GALT6 in four additional individuals (P9–
P12) who had phenotypes compatible with EDS-PF (Table
1 and Figure S3) but in whom no B4GALT7 mutations
had been found. Sanger sequencing of the EDS-PF-like
subjects revealed that all were compound heterozygotes
for B3GALT6 mutations (Table 2). There were two frame-
shift mutations and one missense mutation (c.925T>A
[p.Ser309Thr]) common in two families (F8 and F9). We
investigated the enzyme function of the missense muta-
tion by using the same assay for SEMD-JL1 missense muta-
tions. The GalT-II activities of p.Ser309Thr-B3GALT6 were
significantly decreased (Figure S4).
Collectively, 11 different mutations in individuals from
10 families were identified in B3GALT6 by a combination
of exome and targeted sequencing (Table 2 and Figure S5).
None of these mutations were detected in more than
200 ethnicity-matched controls or in public databases,
including the 1000 Genomes database, indicating that932 The American Journal of Human Genetics 92, 927–934, June 6, 2they are unlikely to be polymorphisms. SEMD-JL1 and
EDS-PF-like individuals had no common mutations
(Table 2). The individuals with B3GALT6 mutations were
short at birth and their short stature worsened with age.
Their common clinical features were a flat face with
prominent forehead and kyphoscoliosis (Table 1). Kypho-
scoliosis was noticed in infancy in most cases and even
in utero in severe cases. Although skeletal changes were
essentially the same, craniofacial and skin abnormalities,
joint laxities, and muscular hypotonia were variable
among the individuals with B3GALT6 mutations. Com-
mon radiographic features were platyspondyly that
becomes less conspicuous with age, short ilia, and elbow
malalignment (Table 1). Prominent lesser trochanters and
metaphyseal flaring were seen in most cases. No individ-
uals showed generalized osteoporosis. The disease pheno-
type was very variable between families (mutations), but
in two familial cases, phenotypes were similar between
the pair of the sibs. As a corollary, our results indicate
that EDS-PF is genetically heterogeneous, with a propor-
tion of cases being caused by mutations in B4GALT7 and
another in B3GALT6.
Diseases caused by defects in enzymes involved in the
biosynthesis of the GAG linker region are categorized as
the GAG linkeropathy. The first member of GAG linkerop-
athy has been identified to arise from an EDS-PF/B4GALT7
deficiency. B4GALT7 mutations have been identified in
homozygous c.808C>T (p.Arg270Cys)12 and compound
heterozygous (c.557C>A [p.Ala186Asp] and c.617T>C
[p.Leu206Pro])11 states. Another member of GAG linkerop-
athymanifests itself as Larsen-like syndrome, B3GAT3 type
(MIM 245600). A family with individuals harboring a ho-
mozygous B3GAT3 (MIM 606374; RefSeq NM_012200.3)
mutation (c.830G>A [p.Arg227Gln]) has been identified.
The clinical features of five affected individuals of the
family are characterized by dislocation and laxity of joints
and congenital heart defects.11 The former considerably
overlaps with the phenotypes of SEMD-JL1 and EDS-PF,
two other GAG linkeropathies; however, the association
of heart defects has critically differentiated this disease
from the others (Figure 1).
Given that the linker region biosynthesis is nonparallel
and that the defects in the three enzymes simply affect
the amounts of the linker region available to form GAGs
(CS, HS, DS), phenotypic similarities of the three diseases
are quite understandable. The quantitative difference of
the phenotypes (severity of the diseases) most probably re-
sults from the difference in the degree of enzyme defects
resulting from mutations. On the other hand, qualitative
differences of the three diseases (e.g., scoliosis caused by
the B3GALT6 mutation, heart disease caused by the
B3GAT3mutation, etc.) suggest other explanations. Tissue
expression patterns of the three genes do not entirely
explain the differences. We examined their mRNA expres-
sion in various human tissues, including cartilage, bone,
and connective tissues by quantitative real-time PCR
(Figure S6). We detected strong expression of B3GALT6 in013
Table 3. The Amount of GAGs in the Lymphoblastoid Cells from
Individuals with Spondyloepimetaphyseal Dysplasia with Joint
Laxity Type 1
Subject
GAG (Disaccharides/mg Acetone Powder)a [pmol]
CS/DS CS DS HS
Control 62 48 29 128
SEMD-JL1
P1 313 295 118 15
P2 345 175 60 21
P3 270 162 28 20
aCalculated based on the peak area in chromatograms of digests with amixture
of chondroitinases ABC and AC-II (CS/DS), chondroitinases AC-I and AC-II (CS),
chondroitinase B (DS), and heparinases I and III (HS).cartilage and bone but only weak expression in skin, liga-
ment, and tendon. B4GALT7 expression was stronger in
cartilage than B3GALT6 and also weak in skin and liga-
ment. B3GAT3 expression was not specific to heart. The
qualitative difference may result from the difference in
the effects of the three genes on GAG formation.
To examine how B3GALT6 mutations affects the prod-
ucts of GAGs in vivo, we measured the amounts of CS
and HS chains at the surface of lymphoblastoid cells
from the subjects by flow cytometry by using CS-stub
and HS-stub antibodies as previously described.13–15 In
brief, purified GAG fractions were treated individually
with a mixture of chondroitinases ABC and AC-II, a
mixture of chondroitinases AC-I (EC 4.2.2.5) (Seikagaku
Corp.) and AC-II (EC 4.2.2.5) (Seikagaku Corp.), chondroi-
tinase B (EC 4.2.2.19) (IBEX Technologies), or a mixture of
heparinases-I and -III (IBEX Technologies) for analyzing
the disaccharide composition of CS/DS, CS, DS, and HS,
respectively. The digests were labeled with a fluorophore
2-aminobenzamide (2AB) and aliquots of the 2AB deriva-
tives of CS/DS/HS disaccharides were analyzed by anion-
exchange HPLC on a PA-03 column (YMC Co.). The
HS-stub antibody (3G10) showed a markedly reduced
binding to the epitopes on the subjects’ cells (Figure S7).
The relative numbers of the HS chains presented as the
mean fluorescence intensity (MFI) of the cell population
stained with the antibody for P1, P2, and P3 were 26%,
56%, and 35% of the control, respectively. On the other
hand, the CS-stub antibody (2B6) showed a similar bind-
ing to the epitopes on the subjects’ cells relative to those
of the control (Figure S7). The MFI for P1, P2, and P3
were 114%, 104%, and 106% of the control, respectively.
Furthermore, we measured disaccharide of GAG chains
from lymphoblastoid cells by using anion-exchange
HPLC after digestion with chondroitinase and heparinase.
The amounts of the disaccharide from HS chains were
significantly decreased, whereas CS and DS chains were
~5 times higher than those in the control (Table 3).
Previous biochemical studies on EDS-PF with B4GALT7
mutations show a reduction in the synthesis of DS
chains.16,17 The c.830G>A (p.Arg227Gln) mutation inThe AmB3GAT3 causes a drastic reduction in GlcAT-I activity in
fibroblasts of the individual with SEMD-JL1 and numbers
of CS and HS chains on the core proteins at the surface
of the fibroblasts are decreased to about half of the
controls.11 Cultured lymphoblastoid cells from individuals
with a c.419C>T (p.Pro140Leu) mutation in B3GAT3 show
that defective synthesis is more pronounced for CS than
for HS.11 Taken together with our results, these findings
suggest that the effects of the deficiencies of the three
enzymes on GAG synthesis are not identical. A possible
explanation for the qualitative phenotypic differences
may be that the biosynthesis of the GAG linker region is
not a simple step-by-step addition but involves parallel
processing and/or alternative pathways. Other glycosyl-
transferases may have similar biochemical functions to
these three enzymes and thus complement their deficient
activities to variable degrees in cell- and/or tissue-specific
manners, leading to differences in the amount of GAGs
in the tissues. It is known that B3GALT6 and B4GALT7
have several homologs.18 It must be noted that all
biochemical studies so far have been performed in vitro
or in cultured cells, and therefore there is a severe limita-
tion to our understanding of the pathogenesis at tissue
and organ levels.
By exome sequencing, we identified loss-of-function
mutations in B3GALT6 in 12 individuals from 10 families.
The mutations produced a spectrum of connective tissue
disorders characterized by lax skin, muscle hypotonia,
joint dislocation, and skeletal dysplasia and deformity,
which include phenotypes previously known as SEMD-
JL1 and EDS-PF (Figures S1 and S2). The pleiotropic pheno-
types of B3GALT6 mutations indicate that B3GALT6 plays
critical roles in development and homeostasis of various
tissues, including skin, bone, cartilage, tendons, and liga-
ments. Biochemical studies that used lymphoblastoid cells
of the individuals with B3GALT6 mutations showed a
decrease of HS and a paradoxical increase of CS and DS
of the cell surface. Further clinical, genetic, and biological
studies are necessary to understand the pathological mech-
anism of the diseases caused by enzyme defects involved in
the biosynthesis of the GAG linker region and roles of the
region in GAG metabolism and function.Supplemental Data
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